Skip to main content
FMS logo

Fresenius Medical Care AG & Co. KGaA (FMS) Stock: Price, Forecast & Analyst Target

Fresenius Medical Care AG & Co. KGaA (FMS) — MoonshotScore 80/100 (Exceptional band), calculated Nov 18, 2026. Price $20.13 (-3.91%), as of the Nov 19, 2026 trading session; market cap $10.5B. Expected results Feb 23, 2027.

Educational signal · not a buy or sell recommendation · How to read this

$20.13 −$0.82 (-3.91%) Market Cap $10.5B

Fresenius Medical Care AG & Co. KGaA · FMS · NYSE · Healthcare · Medical - Care Facilities

Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories.

Price as of Nov 19, 2026

Key Statistics

80 of 100

MoonshotScore v2 · Fresenius Medical Care AG & Co. KGaA (FMS)

Exceptional
Business Quality Solid (72)
Financial Safety Okay (40)
Valuation Cheap (92)
Growth Durability Compounding (86)
Momentum Rising (72)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality and durable growth, at a dirt-cheap price, though the balance sheet is only middling; the market is already moving on it. The score also carries a risk penalty for a bankruptcy-risk score in the grey zone. Business Quality: Solid; Financial Safety: Okay; Valuation: Cheap; Growth Durability: Compounding; Momentum: Rising.

  • EPS beat 0 of the last 4 reports
  • Altman Z 1.71 · Piotroski F 8
  • ROE 7.8% · ROA 3.9% · current ratio 0.99

Helping: business quality, an attractive price, durable growth, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for FMS (52 recorded, newest six shown)
RecordedScoreBand
82Exceptional
81Exceptional
82Exceptional
82Exceptional
80Exceptional
80Exceptional

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$20.13
Change on the day-3.91%
52-week range$20.02–$26.42
Market capitalisation$10.5B—
Price / earnings (trailing)13.28
Shares traded on the day2.10M
Beta (volatility vs the S&P 500)0.76
Dividends per share (last 12 months)$0.86
Dividend yield (last 12 months)3.99%

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $20, high $27, latest $20. 4 reported quarters marked, 2 above and 2 below the recorded estimate. 1 other dated event marked. $27 $20 high $27 Feb 24, 2026 · Earnings results · reported above the recorded estimate · close $231May 5, 2026 · Earnings results · reported below the recorded estimate · close $222Aug 3, 2026 · Earnings results · reported above the recorded estimate · close $263Nov 3, 2026 · Earnings call · management outlook · no recorded estimate to compare · close $234Nov 3, 2026 · Earnings results · reported below the recorded estimate · close $235 Oct 17, 2025 Nov 19, 2026 · $20 $27Oct 17, 2025$27Oct 31, 2025$23Nov 14, 2025$24Nov 28, 2025$24Dec 12, 2025$24Dec 26, 2025$23Jan 9, 2026$22Jan 23, 2026$24Feb 6, 2026$24Feb 20, 2026$23Mar 6, 2026$22Mar 20, 2026$22Apr 2, 2026$23Apr 17, 2026$22May 1, 2026$22May 15, 2026$22May 29, 2026$23Jun 12, 2026$23Jun 26, 2026$24Jul 10, 2026$25Jul 24, 2026$24Aug 7, 2026$23Aug 21, 2026$23Sep 4, 2026$22Sep 18, 2026$22Oct 2, 2026$22Oct 16, 2026$22Oct 30, 2026$22Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · above the recorded estimate
  • · Earnings results · below the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings call · management outlook
  • · Earnings results · below the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate

Management outlook

  • Based on our prior communications of a stronger first half and more pressured second half, driven by TDAPA headwinds, and that we're 10 months finished with the year, for operating income development, we are narrowing our outlook for 2026.

    Shervin Korangy · Statement from

  • When you look at 2027 from a TDAPA perspective, since we do have now the rate, we do expect an operating income headwind, and it is still a bit early, but because it depends a bit on volume and pricing, on how the drugs develop, but we do expect an operating income headwind for 2027 between EUR 300 million and EUR 350 million based on the expiry that are TDAPA-related.

    Martin Fischer · Statement from

How to read these dates

A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.

Read management statements

Other perspectives

Council score for Fresenius Medical Care AG & Co. KGaA (FMS): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Neutral
Valuation Strong
Growth Durability Strong
Momentum Moderate

Legends Council

4 lenses, 4 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Griffin-style lens (simulated) Ken Griffin Unfavorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Favorable read

Read on: Nov 19, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Neutral
Margin of Safety Undervalued
Profit Margin Weak
Debt/Equity Weak
ROE Neutral
Gross Margin Neutral

Read on: Nov 19, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

One of these lenses reads this company less favourably than the MoonshotScore does: Griffin-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

The Munger lens reads the current price as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Fresenius Medical Care AG & Co. KGaA (FMS), and what does it report?

Short answer

Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Fresenius Medical Care AG & Co. KGaA (FMS) is listed on NYSE. Healthcare / Medical Care Facilities SEC filing business address: Else-Kroener Strasse 1, BAD Homburg, 2M, 61352. It employs 108,165 people and is led by Shervin J. Korangy. The market values it at $10.5B.

2 · Latest results

What do the latest results show for Fresenius Medical Care AG & Co. KGaA (FMS)?

Short answer · as of

Against analyst estimates the company has EPS beat 0 of the last 4 reports.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$5.53B Nov 3, 2026
Latest report · revenue estimate
$5.52B Nov 3, 2026
Latest report · revenue vs estimate
Above estimate Nov 3, 2026
Latest report · EPS vs estimate
Below estimate Nov 3, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Nov 3, 2026$5.53B$5.52B$0.6400$0.6510
Aug 3, 2026$5.60B$5.48B$0.6600$0.6160
May 5, 2026$5.40B$5.41B$0.5300$0.5900
Feb 24, 2026$5.97B$5.67B$0.8300$0.6470
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025€4.88B€275M€0.47 (diluted)
Q4 FY2025€5.07B€327M€0.57 (diluted)
Q1 FY2026€4.61B€118M€0.21 (diluted)
Q2 FY2026€4.86B€218M€0.41 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Fresenius Medical Care AG & Co. KGaA (FMS)?

Short answer

The MoonshotScore pillars rate business quality, an attractive price, durable growth, positive momentum as strengths. The distress and quality screens read Altman Z 1.71 · Piotroski F 8. Trailing ratios: ROE 7.8% · ROA 3.9% · current ratio 0.99.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of 1.71 sits in the distress zone (elevated bankruptcy risk).
  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
4 · What to check next?

What should you watch next at Fresenius Medical Care AG & Co. KGaA (FMS)?

Short answer · as of

The next earnings report is expected on Feb 23, 2027. Current published price targets run low $19.90 · high $25.80 · consensus $23.67 · median $24.50 against a quoted price of $20.13 (as of Nov 19, 2026).

What management is planning

Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.

  1. We will give a qualification when we give the 2027 guidance and outlook.

    Martin Fischer ·

2 more statements are quoted under Upcoming events

What the records here don't tell us

  • Detailed statement figures are not shown because their conversion to USD has not been verified.
  • No insider Form 4 transaction falls inside the window this page reads.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Fresenius Medical Care AG & Co. KGaA compare with its peers?

Short answer

Fresenius Medical Care AG & Co. KGaA's score ranks 7th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Tenet Healthcare Corporation (THC) Named competitor$271.34 Nov 18, 2026$21.6B94 5-pillar Nov 18, 2026
LifeStance Health Group, Inc. (LFST) Same industry, near in market value$13.77 Nov 18, 2026$5.24B92 5-pillar Nov 18, 2026
Universal Health Services, Inc. (UHS) Same industry, near in market value$186.07 Nov 18, 2026$10.7B91 5-pillar Nov 18, 2026
Chemed Corporation (CHE) Same industry, near in market value$551.33 Nov 19, 2026$7.15B85 5-pillar Nov 18, 2026
Option Care Health, Inc. (OPCH) Same industry, near in market value$31.61 Nov 19, 2026$4.74B85 5-pillar Nov 18, 2026
Encompass Health Corporation (EHC) Same industry, near in market value$132.25 Nov 19, 2026$13.0B81 5-pillar Nov 18, 2026
Fresenius Medical Care AG & Co. KGaA (FMS) — this page$20.13$10.5B80
DaVita Inc. (DVA) Named competitor$156.24 Nov 19, 2026$9.83B76 5-pillar Nov 18, 2026
National HealthCare Corporation (NHC) Same industry, near in market value$201.60 Nov 18, 2026$3.16B76 5-pillar Nov 18, 2026
The Ensign Group, Inc. (ENSG) Same industry, near in market value$176.59 Nov 19, 2026$10.3B74 5-pillar Nov 18, 2026
Royalty Pharma plc (RPRX) Named competitor$68.67 Nov 18, 2026$39.5B73 5-pillar Nov 18, 2026
Solventum Corporation (SOLV) Named competitor$85.80 Nov 19, 2026$14.6B66 5-pillar Nov 18, 2026
MiniMed Group, Inc. Common Stock (MMED) Same industry, near in market value$16.26 Nov 19, 2026$4.57B38 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$19.90 – $25.80
Consensus target
$23.67
Median target
$24.50

Consensus record · Captured .

Measured against a quoted price of $20.13 (as of Nov 19, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Institutional ownership
7.7% Period end Sep 30, 2026
Previous quarter · ownership
7.7% Prior to period end Sep 30, 2026
Reporting holders
231 Period end Sep 30, 2026
Previous quarter · holders
243 Prior to period end Sep 30, 2026
Holders in provider snapshotShares
Pzena Investment Management LLC16,617,575
Morgan Stanley4,424,999
Dodge & Cox3,328,110
Brandes Investment Partners, LP1,969,749
Todd Asset Management LLC1,761,483

Tracked investors

Which of the 16 named investors we follow held FMS in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported FMS in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Fresenius Medical Care AG & Co. KGaA (FMS)?

Read these with our analysis →

FMS Healthcare Stock FAQ

Research dated 2026-09-13; the full attribution is under Sources. The last 3 questions are answered from this page's own dated data, not from the research.

What does Care Enablement contribute to Fresenius Medical Care?

Care Enablement supplies dialysis machines, dialyzers, solutions, bloodlines, medicines and related systems to treatment providers. Management is using Reignite to pursue margin improvement in this business while absorbing inflationary pressure linked to the Middle East conflict.

How does home dialysis fit into Fresenius Medical Care’s model?

Home dialysis extends the company beyond clinic-based treatment: Fresenius Medical Care provides equipment, patient training, clinical oversight, ongoing assistance and coordinated supply deliveries. Demand therefore includes continued support and consumables as well as the initial equipment placement.

What is the FMS stock price today?

The last price recorded for Fresenius Medical Care AG & Co. KGaA (FMS), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the FMS price target?

The analyst consensus price target for Fresenius Medical Care AG & Co. KGaA (FMS), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Does FMS pay a dividend?

Yes. The dividend yield of Fresenius Medical Care AG & Co. KGaA (FMS) over the last 12 months, with its date, is listed under Price & valuation on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 53 figures on this page — 2 from SEC filings and earnings calls, 42 from Financial Modeling Prep (FMP), 3 with no recorded source, 4 computed by us, formula shown in the register and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • FAQ: What does Care Enablement contribute to Fresenius Medical Care?: Business description; Management outlook — dated call excerpts
  • FAQ: How does home dialysis fit into Fresenius Medical Care’s model?: Business description
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.